Marks the latest big pharma partnership for CureVac around its Covid vaccine candidate, CVnCoV
CureVac N.V. and Novartis AG have signed an initial agreement for the manufacturing of CureVac’s Covid-19 vaccine candidate, CVnCoV. Preparations for the start of production, technology transfers and test runs have already begun. Once the companies reach a final agreement, Novartis plans to manufacture the mRNA and bulk drug product of CVnCoV for up to 50 million doses by the end of 2021, and up to an additional 200 million doses in 2022. Delivery from the manufacturing site in Kundl, Austria, is expected to start this summer.
CureVac started building an integrated European vaccine manufacturing network with various contract development and manufacturing organization (CDMO) partners in the fall of 2020. So far, CureVac is working with Bayer, GlaxoSmithKline and Fareva, among others.
The vaccine has been in Phase IIb/III clinical trials since December. And as of last month, CureVac has started a rolling review with the European Medicines Agency (EMA).
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.